Celgene Co. (NASDAQ:CELG)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $100.57, but opened at $103.40. Celgene shares last traded at $104.70, with a volume of 4,342,675 shares traded.
CELG has been the subject of several analyst reports. Mizuho restated a “hold” rating and set a $100.00 target price on shares of Celgene in a research report on Sunday. ValuEngine downgraded Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. BidaskClub upgraded Celgene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. Cowen restated a “hold” rating and set a $102.00 target price on shares of Celgene in a research report on Tuesday, July 30th. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a research report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, seventeen have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $94.60.
The company has a 50-day simple moving average of $99.38 and a 200-day simple moving average of $95.68. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.32 and a current ratio of 3.44. The stock has a market cap of $72.96 billion, a P/E ratio of 13.76, a P/E/G ratio of 0.52 and a beta of 1.42.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.22 billion. During the same quarter in the previous year, the company posted $2.16 EPS. The business’s revenue for the quarter was up 15.4% compared to the same quarter last year. As a group, sell-side analysts expect that Celgene Co. will post 9.96 earnings per share for the current fiscal year.
In other Celgene news, insider Terrie Curran sold 11,338 shares of Celgene stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $98.27, for a total value of $1,114,185.26. Following the completion of the transaction, the insider now owns 13,493 shares in the company, valued at approximately $1,325,957.11. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.39% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of CELG. First PREMIER Bank bought a new stake in shares of Celgene during the third quarter worth $26,000. Liberty Wealth Management LLC raised its position in shares of Celgene by 212.8% during the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 200 shares during the last quarter. Massey Quick Simon & CO. LLC bought a new stake in shares of Celgene during the second quarter worth $33,000. Lenox Wealth Advisors LLC bought a new stake in shares of Celgene during the third quarter worth $37,000. Finally, Capital Investment Advisory Services LLC raised its position in shares of Celgene by 69.3% during the third quarter. Capital Investment Advisory Services LLC now owns 408 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 167 shares during the last quarter. Hedge funds and other institutional investors own 72.49% of the company’s stock.
Celgene Company Profile (NASDAQ:CELG)
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Stock Portfolio Tracker
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.